Oscar Health, Inc. (OSCR)
NYSE: OSCR · Real-Time Price · USD
27.53
-0.14 (-0.51%)
Aug 11, 2026, 10:54 AM EDT - Market open
Oscar Health Revenue
Oscar Health had revenue of $4.88B in the quarter ending June 30, 2026, with 70.40% growth. This brings the company's revenue in the last twelve months to $15.32B, up 42.82% year-over-year. In the year 2025, Oscar Health had annual revenue of $11.70B with 27.50% growth.
Revenue (ttm)
$15.32B
Revenue Growth
+42.82%
P/S Ratio
0.56
Revenue / Employee
$6,645,828
Employees
2,305
Market Cap
8.49B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.70B | 2.52B | 27.50% |
| Dec 31, 2024 | 9.18B | 3.31B | 56.54% |
| Dec 31, 2023 | 5.86B | 1.90B | 47.92% |
| Dec 31, 2022 | 3.96B | 2.12B | 115.57% |
| Dec 31, 2021 | 1.84B | 1.38B | 297.30% |
| Dec 31, 2020 | 462.80M | -25.39M | -5.20% |
| Dec 31, 2019 | 488.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 450.13B |
| CVS Health | 412.65B |
| The Cigna Group | 282.38B |
| Elevance Health | 201.11B |
| Centene | 180.30B |
| Humana | 145.68B |
| Molina Healthcare | 42.47B |
| Alignment Healthcare | 4.58B |
OSCR News
- 4 days ago - Oscar Health price target raised to $26 from $20 at UBS - TheFly
- 4 days ago - Oscar Health price target raised to $27 from $19 at Baird - TheFly
- 4 days ago - Oscar Health price target raised to $39 from $35 at Barclays - TheFly
- 4 days ago - Oscar Health price target raised to $25 from $13 at BofA - TheFly
- 4 days ago - GoodRx and Oscar Health Tout Tech as Consumer Needs Change - PYMNTS
- 4 days ago - Oscar Health price target raised to $39 from $35 at Barclays - TheFly
- 5 days ago - Oscar Health Earnings Call Transcript: Q2 2026 - Transcripts
- 5 days ago - Oscar Health Earnings release: Q2 2026 - Filings